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Developmental pharmacology is an area of re-
search with which I have been associated since
1955. My major interests have concerned the
processes of chemical and drug metabolism and
how these change from fetus, to newborn, to
adult, to the aged; all ofmy work has been done in
animals. The discipline of developmental pharma-
cology, if we can refer to it as that, is an out-
growth of a very real therapeutic dilemma-how
to treat illness and disease with drugs in the very
young or very old patient.
When I first began my work in this area in the
early 1950's, few data were available about the
reasons for differences in drug response between
newborns, young adult, and aged animals. Out-
side a few research-oriented centers there was
little awareness that very young patients were
perhaps not just very small adults for purposes of
calculating drug dosage.
It has been fairly easy to propose reasons for
drug actions being different in fetus and newborn
and to test some of these hypotheses. This was
not so easily done in the very old animal, and even
today, developmental pharmacology almost al-
ways uses young, not aged, subjects.
Major determinants of drug effects include the
processes of disposition-absorption, distribution
including storage, metabolism, and excretion-as
well as interaction between drug and receptor
sites.
Drug-receptor site interactions at the time I
first entered the field were relatively difficult to
isolate, identify, and quantify. The result of drug-
receptor interactions-namely, drug response-is
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not what I am talking about, though in very
young animals, even this latter is often not easy
to study. At present, this interaction of drug and
receptor is the most neglected area of develop-
mental pharmacology, in my opinion. We now
have some elegant new tools for carrying out such
drug-receptor interaction studies and I hope they
will soon be made in increasing numbers. The rel-
ative lack of research in this area is emphasized
by the program of this session: no one is sched-
uled to talk about it and I doubt that it will be
more than a peripheral issue of any speaker at
this conference.
Yet we know that receptor sites for drugs and
chemicals are different in the fetus, newborn, and
adult and are probably different in the aged. We
know these differences are quantitative and
probably qualitative as well. Myriad examples
can be given for almost all classes ofdrugs-these
are not often remembered and even less ex-
plained or subjected to experimental study.
Even in the areas where we have spent most of
our efforts-disposition-there is a lot of uncov-
ered territory. We now have considerable in-
formation about drug metabolism in the liver of
fetus, newborn, and adult. We do not know to
what extent the changes seen in hepatic drug
metabolism in the aged are the result of liver
damage and to what extent they are due to un-
complicated senescence (if there is such a thing).
We know very little about drug metabolism in
organs other than the liver. My own laboratory
has done quite a bit of work on drug and chemical
metabolism by extrahepatic tissues, but there is
much left to do, especially with humans. Consid-
erable controversy has arisen as to the develop-
ment of drug-metabolism enzymes in human ver-
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thus far, drug metabolism by liver is very low or
absent in the fetus until just before birth. In a
variety of studies done on abortuses both here
and in Scandinavia there appears to be measur-
able drug metabolism in mid- and late-term fe-
tuses. Perhaps Dr. Lucier will speak to this prob-
lem, but, suffice to say, at this point-in drug
metabolism-the area where more work has been
done than any other-we still have large gaps in
our knowledge of differences in function between
fetal, newborn, adult, and aged animals and
humans, and outside of one organ-the liver-we
have virtually no knowledge at all.
Other processes of disposition have been even
less studied. Recently some good studies on renal
and biliary excretion of drugs and chemicals in
newborn and adult animals have been made. A
few studies on distribution and storage of chem-
icals in fetal, newborn, and adult animals have in-
dicated differences in these processes with age as
well. Whole body autoradiography has been es-
pecially helpful in these studies of chemical
distribution and storage at different ages.
Occasionally a report has been made of differ-
ences between adult and young animals in the
binding of drugs. Most of these studies deal with
serum protein-drug interactions and are often
confounded by both the qualitative and quantita-
tive differences between adult and fetal blood
constituents and proteins. Few if any studies
have been made on differences between adult and
fetal or newborn tissue binding of drugs; this also
gets back to the original consideration I made
concerning drug-receptor interactions, since re-
ceptors for most drugs are in tissues, not blood.
Pharmacokinetics can tell us much about proc-
esses of disposition, so I look forward to hearing
from Dr. Singh about the developmental pharma-
cokinetics. I think the application of this tool to
developmental pharmacology is long overdue,
and I hope the results of these studies will be as
useful as I feel they will be.
Finally, the role of both environment and he-
redity in the development of all systems interact-
ing with drugs has been very much neglected un-
til recently. From all we know, it seems likely
that both environment and heredity will have
determining roles at all ages in how a drug is
handled, as well as what drug receptors are
available, what their affinity for the drug will be,
and what will be their intrinsic power to cause
effects after they have reacted with the drug. It
seems reasonable to expect that subsets of our
population will have drug handling and drug re-
ceptor mechanisms that are different, both qual-
itatively and quantitatively, as determined by
genetics. It also seems probable that environmen-
tal factors can influence these drug handling and
drug receptor systems differently in genetically
different subsets of a population. I look forward
to hearing what Dr. Nebert has to say about this
aspect ofthe field.
In short, we will consider a few of the very ac-
tive areas of research in developmental pharma-
cology. We certainly need to remember that our
knowledge even in the best-researched aspects is
only rudimentary. I hope this session can clearly
identify where future work may be most produc-
tive.
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